WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), announced that Targacept management will conduct a conference call and audio webcast today at 10:00 a.m. Eastern Standard Time regarding the company’s global collaboration with AstraZeneca for late-stage product candidate TC-5214 for the treatment of major depressive disorder which was announced earlier this morning.
